← Back to Screener
Beta Bionics, Inc. Common Stock (BBNX)
Price$12.91
Favorite Metrics
Price vs S&P 500 (26W)-47.03%
Price vs S&P 500 (4W)11.82%
Market Capitalization$576.08M
All Metrics
Book Value / Share (Quarterly)$6.48
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)724.29%
Cash Flow / Share (Quarterly)$-1.27
Price vs S&P 500 (YTD)-61.54%
Gross Margin (TTM)55.40%
Net Profit Margin (TTM)-73.02%
EPS (TTM)$-1.95
10-Day Avg Trading Volume1.28M
EPS Excl Extra (TTM)$-1.95
EPS (Annual)$-1.81
ROI (Annual)-25.45%
Gross Margin (Annual)55.40%
Cash / Share (Quarterly)$4.94
Revenue Growth QoQ (YoY)57.15%
ROA (Last FY)-22.27%
EBITD / Share (TTM)$-2.04
Operating Margin (TTM)-71.50%
Cash Flow / Share (Annual)$-1.27
P/B Ratio2.00x
P/B Ratio (Quarterly)4.66x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)5.43x
ROA (TTM)-22.07%
EPS Incl Extra (Annual)$-1.81
Current Ratio (Annual)8.66x
Quick Ratio (Quarterly)7.73x
3-Month Avg Trading Volume1.23M
52-Week Price Return18.65%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)5.75x
Asset Turnover (Annual)0.30x
52-Week High$32.71
EPS Excl Extra (Annual)$-1.81
26-Week Price Return-38.28%
Quick Ratio (Annual)7.73x
13-Week Price Return-23.60%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.66x
Enterprise Value$544.504
Asset Turnover (TTM)0.30x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.55x
Pretax Margin (Annual)-73.02%
Cash / Share (Annual)$4.94
3-Month Return Std Dev78.46%
Net Income / Employee (TTM)$-0
ROE (Last FY)-25.45%
EPS Basic Excl Extra (Annual)$-1.81
Receivables Turnover (TTM)6.34x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.95
Receivables Turnover (Annual)6.34x
ROI (TTM)-24.45%
P/S Ratio (TTM)5.75x
Revenue / Share (Annual)$2.47
Price vs S&P 500 (52W)-16.45%
Year-to-Date Return-57.40%
5-Day Price Return22.11%
EPS Normalized (Annual)$-1.81
Net Profit Margin (Annual)-73.02%
Month-to-Date Return29.54%
EBITD / Share (Annual)$-2.04
Operating Margin (Annual)-71.50%
EPS Basic Excl Extra (TTM)$-1.95
P/B Ratio (Annual)4.66x
Inventory Turnover (TTM)2.55x
Pretax Margin (TTM)-73.02%
Book Value / Share (Annual)$6.48
Price vs S&P 500 (13W)-26.47%
Beta0.79x
Revenue / Share (TTM)$2.27
ROE (TTM)-24.45%
52-Week Low$8.80
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.31
4.12
4.12
4.11
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
BBNXBeta Bionics, Inc. Common Stock | 5.75x | — | 55.40% | -71.50% | $12.91 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Beta Bionics is a commercial-stage medical device company developing the iLet Bionic Pancreas, an automated insulin delivery system using adaptive closed-loop algorithms for people with insulin-dependent diabetes. The company's proprietary technology is designed to simplify diabetes management and improve patient outcomes by automating insulin dosing. Beta Bionics operates a focused business model centered on the development, manufacturing, and commercialization of the iLet platform.